A randomised trial of short- vs long-term androgen deprivation with salvage radiotherapy for biochemical failure following radical prostatectomy: URONCOR 06-24.

BACKGROUND: Salvage radiotherapy (SRT) and androgen-deprivation therapy (ADT) are widely used in routine clinical practice to treat patients with prostate cancer who develop biochemical recurrence (BCR) after radical prostatectomy (RP). However, there is no standard-of-care consensus on optimal duration ADT. Investigators propose three distinct risk groups in patients with prostate cancer treated with SRT in order to better define the indications and duration of ADT combined with SRT. STUDY DESIGN: The URONCOR 06-24 trial (ClinicalTrials.gov identifier NCT05781217) is a prospective, multicentre, randomised, open-label, phase III, clinical trial. The aim of the trial is to determine the impact of short-term (6 months) vs long-term (24 months) ADT in combination with SRT on distant metastasis-free survival (MFS) in patients with prostate cancer with BCR after RP (intermediate and high risk). ENDPOINTS: The primary endpoint is 5-year MFS rates in patients with prostate cancer treated with long- vs short-term ADT in combination with SRT. Secondary objectives are biochemical-relapse free interval, pelvic progression-free survival, time to start of systemic treatment, time to castration resistance, cancer-specific survival, overall survival, acute and late toxicity, and quality of life. METHODS AND ANALYSIS: Total of 534 patients will be randomised 1:1 to ADT 6 months or ADT 24 months with a luteinizing hormone-releasing hormone analogue in combination with SRT, stratified by risk group and pathological lymph node status. ETHICS AND DISSEMINATION: The study is conducted under the guiding principles of the World Medical Association Declaration of Helsinki. The results will be disseminated at research conferences and in peer-reviewed journals. TRIAL REGISTRATION NUMBER: EudraCT number 2021-006975-41.

Novel Approaches in the Systemic Management of High-Risk Prostate Cancer.

Locally advanced prostate cancer comprises approximately 20% of new prostate cancer diagnoses. For these patients, international guidelines recommend treatment with radiotherapy (RT) to the prostate in combination with long-term (2-3 years) androgen deprivation therapy (ADT), or radical prostatectomy in combination with extended pelvic lymph node dissection (PLND) as another treatment option for selected patients as part of multimodal therapy. Improvements in overall survival with docetaxel or an androgen receptor signaling inhibitor have been achieved in patients with metastatic castration sensitive or castration resistant prostate cancer. However, the role of systemic therapy combinations for high risk and/or unfavorable prostate cancer is unclear. In this context, the aim of this review is to assess the current evidence for systemic treatment combinations as part of primary definitive therapy in patients with high-risk localized prostate cancer.

[The Alliance for the Prevention of Colorectal Cancer in Spain. A civil commitment to society]. / Alianza para la Prevención del Cáncer de Colon en España: un compromiso cívico con la sociedad.

Colorectal cancer (CRC) is the most common malignant tumor in Spain, when men and women are considered together, and the second leading cause of cancer death. Every week in Spain over 500 cases of CRC are diagnosed, and nearly 260 people die from the disease. Epidemiologic estimations for the coming years show a significant increase in the number of annual cases. CRC is a perfectly preventable tumor and can be cured in 90% of cases if detected in the early stages. Population-based screening programs have been shown to reduce the incidence of CRC and mortality from the disease. Unless early detection programs are established in Spain, it is estimated that in the coming years, 1 out of 20 men and 1 out of 30 women will develop CRC before the age of 75. The Alliance for the Prevention of Colorectal Cancer in Spain is an independent and non-profit organization created in 2008 that integrates patients' associations, altruistic non-governmental organizations and scientific societies. Its main objective is to raise awareness and disseminate information on the social and healthcare importance of CRC in Spain and to promote screening measures, early detection and prevention programs. Health professionals, scientific societies, healthcare institutions and civil society should be sensitized to this highly important health problem that requires the participation of all sectors of society. The early detection of CRC is an issue that affects the whole of society and therefore it is imperative for all sectors to work together.

Extreme Hypofractionation with SBRT in Localized Prostate Cancer.

Prostate cancer is the most commonly diagnosed cancer among men around the world. Radiotherapy is a standard of care treatment option for men with localized prostate cancer. Over the years, radiation delivery modalities have contributed to increased precision of treatment, employing radiobiological insights to shorten the overall treatment time, improving the control of the disease without increasing toxicities. Stereotactic body radiation therapy (SBRT) represents an extreme form of hypofractionated radiotherapy in which treatment is usually delivered in 1-5 fractions. This review assesses the main efficacy and toxicity data of SBRT in non-metastatic prostate cancer and discusses the potential to implement this scheme in routine clinical practice.

Indicaciones del tratamiento radioterápico en el cáncer de mama / Indications for radiotherapy treatment of breast cancer

Objetivo: El cáncer de mama es la primera causa de muerte por cáncer en la mujer en Estados Unidos. Esta patología es igualmente frecuente en Europa y forma parte de las consultas diarias de los Servicios dedicados a la oncología (Oncología Radioterápica, Cirugía General, Ginecología, y Oncología Médica), aunque cada vez hay más Servicios implicados en el manejo de estas pacientes (Atención Primaria, Nutrición, Psico-oncología, Rehabilitación, Unidad del Dolor, Enfermería): La revisión de las indicaciones del tratamiento radioterápico permite acercar esta modalidad terapéutica al resto de Especialidades Método: Exposición de todas las situaciones clínicas susceptibles de radioterapia. Resultado: Existe evidencia científica que demuestra la necesidad de administrar radioterapia para disminuir el riesgo de recidiva loco-regional y ello influye en la supervivencia global. Conclusiones: El cáncer de mama precisa un abordaje terapéutico multidisciplinar siendo la radioterapia indispensable en el tratamiento conservador y en otros muchos casos (AU)

Purpose: Breast cancer is the first leading cancer-related cause of death among USA women. In Europe, breast cancer occurs as frequently as in the United States an thus we encounter this pathology on a regular basis in Oncology Services such as Radiation Oncology, General Surgery, Gynecology and Medical Oncology. Nevertheless, the number of services working with this kind of patients is increasing; Primary Health Care, Nutrition, Psycho-oncology, Rehabilitation centers, Pain Clinics and Nursing among others. Reviewing radiotherapy treatment indications shall bring this modality and its procedures closer to other medical specialties. Methods: Exposition of all clinical indications that might include radiotherapy treatment. Results: There is scientific evidence that proves that radiotherapy is needed in order to reduce locoregional risk of recurrence, which shall determine global survival. Conclusions: Breast cancer requires a multidisciplinary therapeutic approach for which radiotherapy is essential in the conservative treatment as well as in other cancer cases (AU)